Vysov-M 50/500 Mg (Vildagliptin/Metformin)

Cipla Limited manufactures Vysov-M 50/500 mg, a fixed‑dose combination tablet indicated for the treatment of Type 2 diabetes mellitus. Each strip contains 15 tablets and the product is offered in pack sizes of 60, 120, and 240 tablets. This medication provides a dual mechanism to improve glycemic control in adults with Type 2 diabetes.

Product Overview

Vysov-M combines Vildagliptin 50 mg and Metformin 500 mg to address two key pathways of glucose regulation. Vildagliptin enhances incretin hormone activity, while Metformin reduces hepatic glucose production and improves peripheral insulin sensitivity. Together they deliver complementary anti‑diabetic effects without the need for multiple separate pills.

What Is Vysov-M

Vildagliptin belongs to the class of dipeptidyl‑peptidase‑4 (DPP‑4) inhibitors. It prolongs the action of glucagon‑like peptide‑1 (GLP‑1) by preventing its degradation, leading to increased insulin secretion when blood glucose rises. Metformin, a biguanide, decreases gluconeogenesis in the liver and enhances muscle glucose uptake. The fixed‑dose formulation ensures that patients receive both agents in a single daily tablet, supporting adherence and simplifying regimen management.

Uses and Benefits

Clinicians prescribe Vysov-M when monotherapy with either Vildagliptin or Metformin fails to achieve target HbA1c levels. Key benefits include:

• Improved post‑prandial and fasting glucose control
• Lower risk of hypoglycemia compared with sulfonylureas
• Weight‑neutral profile, which supports long‑term cardiovascular health
• Convenient once‑daily dosing that enhances patient compliance

Real‑world studies have demonstrated average HbA1c reductions of 1.0 % to 1.5 % when Vysov-M is used as an adjunct to diet and exercise. The combination also shows favorable effects on lipid parameters and blood pressure, further contributing to overall cardiometabolic risk reduction.

How It Works

The therapeutic synergy of Vildagliptin and Metformin stems from their distinct but complementary mechanisms. By preserving GLP‑1 activity, Vildagliptin stimulates glucose‑dependent insulin release from pancreatic beta cells, reducing post‑prandial spikes. Metformin suppresses hepatic glucose output and increases insulin‑sensitive glucose disposal in muscle and adipose tissue. This dual action results in a more balanced glucose profile throughout the day, minimizing both fasting and post‑prandial hyperglycemia.

Pharmacokinetic studies indicate that Vildagliptin is eliminated primarily through hepatic metabolism, while Metformin is cleared renally without extensive metabolism. The distinct elimination pathways reduce the likelihood of drug‑drug interactions, making the combination suitable for many patients on complex medication regimens.

Dosage Guidelines

Adults typically start with one 50/500 mg tablet taken orally once daily with the morning meal. The dose may be titrated based on glycemic response, renal function, and tolerability. For patients with moderate renal impairment (eGFR 30‑45 mL/min/1.73 m²), a reduced frequency of every other day is recommended to avoid Metformin accumulation.

Patients should swallow the tablet whole; crushing or chewing is discouraged because it may alter the release profile. Regular monitoring of renal function, hepatic enzymes, and blood glucose is advised during therapy to ensure safety and efficacy.

Side Effects

Most adverse events are mild and include:

• Gastrointestinal discomfort such as nausea, abdominal pain, or diarrhea
• Headache
• Upper respiratory tract infections
• Skin rash or pruritus

Rare but serious complications may involve lactic acidosis, particularly in individuals with compromised renal function, and pancreatitis. Patients experiencing persistent vomiting, severe abdominal pain, or unexplained muscle weakness should seek immediate medical attention.

Warnings and Precautions

Prior to initiating Vysov-M, healthcare providers should evaluate:

• Renal function – Metformin is contraindicated when eGFR falls below 30 mL/min/1.73 m².
• History of pancreatitis, alcohol abuse, or hepatic disease.
• Concomitant use of other antidiabetic agents that may increase hypoglycemia risk, such as insulin or sulfonylureas.

Pregnant or breastfeeding women should avoid this medication unless the anticipated benefit justifies potential risks. Patients planning pregnancy should discuss alternative therapies with their physician.

For detailed scientific references, see the National Institutes of Health (NIH), the U.S. Food and Drug Administration (FDA), and MedlinePlus.

Frequently Asked Questions

1. What is the recommended starting dose of Vysov-M?

The usual starting dose is one 50/500 mg tablet taken once daily with the morning meal. Dose adjustments are individualized based on glycemic response and tolerability.

2. Can Vysov-M be used in patients with kidney disease?

Metformin accumulation is a concern in moderate to severe renal impairment. Patients with an eGFR of 30‑45 mL/min/1.73 m² may require dose reduction, while those with an eGFR below 30 mL/min/1.73 m² should not use the medication.

3. Does Vysov-M cause weight gain?

Clinical data indicate that Vysov-M is weight‑neutral. Unlike some sulfonylureas, it does not typically lead to significant weight gain when used as monotherapy or in combination with other agents.

4. How long does it take to see a reduction in HbA1c?

Patients often experience a measurable decline in HbA1c after 8‑12 weeks of consistent therapy, although individual response may vary depending on baseline glucose levels and adherence.

5. Are there any dietary restrictions while taking Vysov-M?

No specific dietary restrictions are required, but patients should follow a balanced, carbohydrate‑controlled diet and maintain regular physical activity to optimize glycemic control.

For additional product information, refer to the Wikipedia entry on Vildagliptin and the Drugs.com database.